首页|亚胺培南西司他丁钠联合小剂量氢化可的松治疗脓毒症休克患者的可行性

亚胺培南西司他丁钠联合小剂量氢化可的松治疗脓毒症休克患者的可行性

扫码查看
目的 分析亚胺培南西司他丁钠联合小剂量氢化可的松治疗脓毒症休克患者的可行性及对血清心型脂肪酸结合蛋白(H-FABP)、降钙素原(PCT)、C-反应蛋白(CRP)水平的影响。方法 选取2020年7月-2022年8月绍兴市中心医院收治的脓毒症休克患者85例,根据治疗方案分为对照组44例与联合组41例,对照组予以小剂量氢化可的松治疗,联合组给予亚胺培南西司他丁钠联合小剂量氢化可的松治疗,比较两组治疗7 d后疗效,病情归转情况,分析治疗前、治疗7 d后血清H-FABP、CRP、PCT、免疫指标水平,记录治疗期间不良反应。结果 治疗7 d后,联合组总有效率为87。80%,高于对照组的68。18%(P<0。05);与对照组比较,联合组机械通气时间、住院时间更短(P<0。05),细菌清除率更高(P<0。05);治疗7 d后,两组全血CD8+及血清H-FABP、CRP、PCT水平下降(P<0。05),且联合组下降更明显(P<0。05);全血CD4+及血清免疫球蛋白G(IgG)、IgM水平上升(P<0。05),且联合组升高更明显(P<0。05);治疗期间,联合组不良反应发生率为24。39%(10/41),与对照组15。91%(7/44)比较,差异无统计学意义。结论 亚胺培南西司他丁钠联合小剂量氢化可的松治疗脓毒症休克患者具有可行性,疗效确切,可促进病情转归,改善血清H-FABP、CRP、PCT水平,降低组织损伤及炎症反应,提高免疫功能,且安全性良好。
Feasibility of imipenem-cilastatin sodium combined with low dose of hydrocortisone in treatment of patients with septic shock
OBJECTIVE To analyze the feasibility of imipenem-cilastatin sodium combined with low dose of hydro-cortisone in treatment of the patients with septic shock and observe the influence on serum heat-fatty acid binding protein(H-FABP),procalcitonin(PCT)and C-reactive protein(CRP).METHODS A total of 85 patients with septic shock who were treated in Shaoxing Central Hospital from Jul 2020 to Aug 2022 were enrolled in the study and were divided into the control group with 44 cases and the combination group with 41 cases according to thera-peutic regimen.The control group was treated with low dose of hydrocortisone,while the combination group was given imipenem-cilastatin sodium combined with low dose of hydrocortisone.The curative effect and treatment outcomes were observed and compared between the two groups after the treatment for 7 days.The levels of serum H-FABP,CRP,PCT and immune indexes were observed and compared before the treatment and after the treat-ment for 7 days.The adverse reactions were recorded during the treatment.RESULTS The total effective rate of the combination group was 87.80%after the treatment for 7 days,higher than 68.18%of the control group(P<0.05).The mechanical ventilation duration and length of hospital stay were shorter in the combination group than in the control group(P<0.05),and the eradication rate of bacteria of the combination group was higher than that of the control group(P<0.05).The levels of whole blood CD8+,serum H-FABP,CRP and PCT of the two groups of patients were reduced after the treatment for 7 days(P<0.05),and the levels of the above indexes of the combination group were reduced more remarkably than those of the control group(P<0.05).The levels of whole blood CD4+,serum immunoglobulin G(IgG)and IgM of the two groups were elevated(P<0.05),and the levels of the above indexes of the combination group were elevated more remarkably than those of the control group(P<0.05).The incidence of adverse reactions of the combination group was 24.39%(10/41)during the treatment,the control group 15.91%(7/44),and there was no significant difference.CONCLUSION Imipenem-cilastatin sodium combined with low dose of hydrocortisone is feasible to treat the patients with septic shock,it can a-chieve exact curative effect,promote the treatment outcome,improve the levels of serum H-FABP,CRP and PCT,re-duce the tissue damage and inflammatory response,and boost the immune function,with the safety favorable.

Septic shockImipenem-cilastatin sodiumHydrocortisoneHeat-fatty acid binding proteinProcalci-toninC-reactive proteinTreatment outcome

王静霞、张涛、胡春琼、贺建华

展开 >

绍兴市柯桥区妇幼保健院急诊科,浙江绍兴 312000

绍兴市妇幼保健院科教科,浙江绍兴 312000

绍兴市中心医院急诊科,浙江绍兴 312000

脓毒症休克 亚胺培南西司他丁钠 氢化可的松 心型脂肪酸结合蛋白 降钙素原 C-反应蛋白 病情归转

浙江省卫生健康科技计划项目

2022KY413

2024

中华医院感染学杂志
中华预防医学会 中国人民解放军总医院

中华医院感染学杂志

CSTPCD北大核心
影响因子:1.885
ISSN:1005-4529
年,卷(期):2024.34(18)